Gland Pharma Limited Share Price & Analysis

Gland Pharma gets approval for Sugammadex Injection

*Gland Pharma gets approval for Sugammadex Injection*. The company received regulatory approval for Sugammadex Injection in two strengths: **200 mg/2 mL** and **500 mg/5 mL**, both as single-dose vials. This expansion enhances its anaesthesia portfolio and strengthens market positioning in the injectables segment. Approval could drive future revenue via market entry or partnerships. 📊 *STOCKS:* $GLAND | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #Pharma

Gland Pharma hosts analyst and investor meet

*Gland Pharma hosts analyst and investor meet.* The company provided updates during the con-call, though no major financial revisions were disclosed. Details focused on operational performance and market outlook. **No significant guidance changes** were announced. 📊 *STOCKS:* $GLAND | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Pharma

Gland Pharma holds annual general meeting

*Gland Pharma holds annual general meeting*\nGland Pharma Limited conducted its Annual General Meeting on August 25, 2026. The company submitted the scrutinizers' report and voting results to the stock exchange. This is a routine corporate exercise with no immediate financial implications.\n\n📊 *STOCKS:* $GLAND | 🏢 *SECTOR:* Pharma | #LOWIMPACT #AGM

MSCI index rejig adds four, drops three Indian stocks

*MSCI index rejig adds four, drops three Indian stocks*. MSCI has added **JSW Infratech**, **Gland Pharma**, **Route Mobile**, and **Star Health** to its India index, effective September 1. Excluded are **BEL**, **Tube Investments**, and **CG Power**. The move may trigger passive inflows into added stocks and outflows from removed ones. 📊 *STOCKS:* JSWINFRATECH, GLAND, ROUTE, STARHEALTH, BEL, TUBEINVEST, CGPOWER | 🏢 *SECTOR:* CapitalMarkets | #MEDIUMIMPACT #IndexRebalance

Gland Pharma gets USFDA nod for generic Sugammadex Injection

*Gland Pharma gets USFDA nod for generic Sugammadex Injection*. This approval allows Gland Pharma to launch its generic version of Sugammadex Injection in the U.S. market. Sugammadex, used to reverse neuromuscular blockade, has a market size of **over $200 million annually**. The move strengthens Gland's position in the sterile injectables segment. 📊 *STOCKS:* $GLAND | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #USFDA

Gland Pharma publishes statutory newspaper notice

*Gland Pharma publishes statutory newspaper notice* The company has released a copy of its newspaper publication as part of regulatory compliance. This is a routine corporate disclosure with no financial impact. Such filings are standard and do not indicate operational changes. 📊 *STOCKS:* GLAND | 🏢 *SECTOR:* Pharma | #LOWIMPACT #corporate filing

Gland Pharma publishes mandatory newspaper notice

*Gland Pharma publishes mandatory newspaper notice.* This is a routine regulatory disclosure required under corporate norms. **No financial or operational impact** is expected from this filing. It does not indicate any change in business prospects or strategy. 📊 *STOCKS:* GLAND | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Regulatory

5 stocks added to MSCI India Standard Index

*5 stocks added to MSCI India Standard Index*. MSCI’s February index review added Dixon, JK Cement, Precision Camshafts, Gland Pharma, and Rossari Biotech. Inclusion may attract passive foreign inflows into these stocks. Index rebalancing impacts global fund tracking MSCI benchmarks. 📊 *STOCKS:* DIXON, JKCEMENT, PRECAM, GLAND, ROSSARI | 🏢 *SECTOR:* Indices | #MEDIUMIMPACT #MSCI

Gland Pharma gets USFDA nod for glaucoma drug

*Gland Pharma gets USFDA nod for glaucoma drug.* The approval boosts its product portfolio and export potential. Shares rose on NSE following the news. The drug’s launch could contribute **revenue of ₹100–150 crore** annually in the medium term. 📊 *STOCKS:* GLAND | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #FDAApproval